{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:43:39Z","timestamp":1792449819378,"version":"4.5.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1055\/a-2820-6384","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:30:28Z","timestamp":1792449028000},"page":"1161-1169","source":"Crossref","is-referenced-by-count":0,"title":["Update IgA-Nephropathie 2025\/2026"],"prefix":"10.1055","volume":"151","author":[{"given":"Severin","family":"Schricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Latus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.kint.2025.10.004","article-title":"From progression to remission: a new paradigm for success in chronic kidney disease","volume":"109","author":"N Tangri","year":"2026","journal-title":"Kidney Int"},{"issue":"S 04","key":"ref2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.003","article-title":"KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","volume":"108","author":"BH Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.03.003","article-title":"Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary","author":"BH Rovin","year":"2026","journal-title":"Kidney Int"},{"issue":"01","key":"ref4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"CK Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"sfae230","DOI":"10.1093\/ckj\/sfae230","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"E Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"issue":"06","key":"ref6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-Term Outcomes in IgA Nephropathy","volume":"18","author":"D Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"03","key":"ref7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ndt\/gfae085","article-title":"Albuminuria predicts kidney events in IgA nephropathy","volume":"40","author":"AL Faucon","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"ref8","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1016\/j.ekir.2025.09.025","article-title":"Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management","volume":"10","author":"J Barratt","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2215\/CJN.0000000961","article-title":"Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy","volume":"21","author":"HJL Heerspink","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"BH Rovin","year":"2023","journal-title":"Lancet"},{"issue":"S 03","key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf116.0313","article-title":"Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the phase 2 SPARTACUS trial #1916","volume":"40","author":"IM Ayoub","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"sfae394","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"M Schanz","year":"2025","journal-title":"Clin Kidney J"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"sfag181","DOI":"10.1093\/ckj\/sfag181","article-title":"Long-Term Real-World Evidence of Sparsentan Efficacy in Patients with IgA Nephropathy Treated with SGLT2 Inhibitors","volume":"19","author":"M Schanz","year":"2026","journal-title":"Clin Kidney J"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in Patients with IgA Nephropathy","volume":"392","author":"HJL Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"R Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"T Rauen","year":"2020","journal-title":"Kidney Int"},{"issue":"19","key":"ref17","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"J Lv","year":"2022","journal-title":"JAMA"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"V Perkovic","year":"2025","journal-title":"N Engl J Med"},{"issue":"07","key":"ref19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA Nephropathy \u2013 Interim Analysis of a Phase 3 Trial","volume":"394","author":"V Perkovic","year":"2026","journal-title":"N Engl J Med"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy","volume":"394","author":"R Lafayette","year":"2026","journal-title":"N Engl J Med"},{"issue":"19","key":"ref21","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa2514415","article-title":"Telitacicept for IgA Nephropathy \u2013 Interim Analysis of a Phase 3 Trial","volume":"394","author":"J Lv","year":"2026","journal-title":"N Engl J Med"},{"issue":"04","key":"ref22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"J Floege","year":"2025","journal-title":"Kidney Int"},{"issue":"04","key":"ref23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial","volume":"36","author":"R Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2820-6384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:30:32Z","timestamp":1792449032000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2820-6384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2026,10,19]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2820-6384","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}